KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).

Katsuyuki Sakanaka, Keita Sasaki, Takahiro Tsushima, Ryunosuke Machida, Yoichi Hamai, Akinori Watanabe, Kota Kawabata, Satoru Matsuda, Ken Kato, Haruhiko Fukuda, Hiroya Takeuchi, Japan Esophageal Oncology Group of the Japan Clinical Oncology Group

BMC Cancer 26(1) 34

PMID41331921
PMCIDPMC12781585
DOI10.1186/s12885-025-15403-2
发表日期2025-12-03
摘要

摘要

BACKGROUND: The immunogenic cell death induced by radiotherapy (RT) has been demonstrated to enhance the systemic antitumor effect of immune checkpoint inhibitors (ICIs). The incorporation of RT into ICIs has the potential to mitigate the occurrence of early treatment failure, particularly with dual ICI combination, in patients with advanced or recurrent esophageal cancer. METHODS: This randomized phase II trial, initiated in November 2024, aims to explore the superiority of the combination of RT with nivolumab plus ipilimumab over nivolumab plus ipilimumab alone in patients with advanced or recurrent esophageal squamous cell carcinoma. The primary endpoint is progression-free survival, while the secondary endpoints include overall survival, response rate, duration of response, and adverse events. We assumed a 6-month PFS of 35% in the nivolumab plus ipilimumab alone arm and expected a 15% increase in the 6-month PFS for the RT with nivolumab plus ipilimumab arm (HR, 0.66). The total required sample size was calculated to be 70 (35 per arm) to achieve a desired power of 80% with an overall one-sided alpha of 20%, an accrual period of 2.5 years, and a follow-up period of 1 year. A total of 74 patients will be enrolled from 41 institutions in Japan. An ancillary study analyzes cytokine profiles and phenotypic characteristics in peripheral blood mononuclear cells during treatment with the protocol. DISCUSSION: The objective of this trial is to assess the safety and efficacy of RT in combination with dual ICIs in reducing early treatment failure and improving outcomes with translational research. Findings from this trial will inform a future phase III trial in this patient population. TRIAL REGISTRATION: This trial has been registered on November 5th, 2024, in the Japan Registry of Clinical Trials as jRCT1031240461 ( https://jrct.mhlw.go.jp/en-latest-detail/jRCT1031240461 ).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。